Presentation (CTI)

OBJECTIVES: To conduct a systematic literature review to identify published evidence on resource use and costs (direct and indirect) in patients with Hidradenitis Suppurativa (HS) who are treated with non-biologics, biologics and/or JAK inhibitors.
METHODS: Literature search was conducted using Medline and EMBASE from January 2015 to October 2025. The study included real world evidence studies reporting costs or resource use in adults (≥18 years) diagnosed with HS.
RESULTS: A total of 340 citations were screened, and 24 studies met the inclusion criteria. Included studies were conducted across six different countries, and were predominantly retrospective cohort studies, with sample sizes ranging from 27 to 54,912. The mean age of study participants ranged from 35 to 47 years, and majority of the participants were women. Commonly reported comorbidities were depression, diabetes, and hypertension. The economic burden of HS is high. Cost estimates and healthcare resource utilization (HCRU) vary widely depending on health care system contexts and on health care resource use requirements. Costs were converted to USD, 2025. The total mean direct costs ranged from 1,1184 USD to 55,236 USD, of which a significant amount of costs were associated with inpatient care. Indirect costs ranged from 1,483 to 4,241 USD, of which absenteeism from work was a major contributor.HCRU for HS varies depending on the context of health care settings. In the United Kingdom and United States, outpatient visits for HS are more common than all other health-seeking visits, including inpatient visits and hospital admissions. Studies in France found that HS significantly impairs work productivity and daily activity, driven by disease severity, pain, and mood disorders.
CONCLUSIONS: This review synthesized evidence on the costs and HCRU associated with HS highlighting early and effective treatment is essential to reduce the personal and economic burden of HS.